ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025.
Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, May 7, 4:30 PM EST
Dial-In: (646) 931-3860
Webinar ID: 885 4355 1292
Passcode: 419231
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.37 |
| Daily Change: | 0.13 2.39 |
| Daily Volume: | 95,041 |
| Market Cap: | US$40.080M |
August 06, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
